Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide
Annie Im(UPMC Hillman Cancer Center), Richard F. Olsson(AstraZeneca (Netherlands)), Leslie Lehmann(Harvard University), Margaret L. MacMillan(University of Minnesota Medical Center), Deepesh Lad(Post Graduate Institute of Medical Education and Research), Vaibhav Agrawal(City Of Hope National Medical Center), Andrew Daly, Mohamed A. Kharfan‐Dabaja(Jacksonville College), Gerhard Hildebrandt(University of Missouri Health System), Navneet S. Majhail(Sarah Cannon), Nosha Farhadfar(University of Florida Health), Rodrigo Martino(Universitat Autònoma de Barcelona), Hemant S. Murthy(University of Florida), Saurabh Chhabra(Medical College of Wisconsin), Medhat Askar(Baylor University Medical Center), Catherine Lee(University of California, Los Angeles), Hannah Choe(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Amer Beitinjaneh(University of Miami), Peiman Hematti(UW Health University Hospital), Michael Byrne(Vanderbilt University Medical Center), Asad Bashey, Jan Černý(Worcester Memorial Hospital), Michael Hemmer(McGill University), Rabi Hanna(Cleveland Clinic), Vijaya Raj Bhatt(Susan Thompson Buffett Foundation), Tracey O’Brien(Sydney Children's Hospital), Taiga Nishihori(Moffitt Cancer Center), Steven Z. Pavletic(National Institutes of Health), Paul Castillo(University of Florida), Usama Gergis(Thomas Jefferson University Hospital), Hisham Abdel‐Azim(University of Southern California), Madan Jagasia(Vanderbilt University Medical Center), Daniel J. Weisdorf(University of Minnesota), Shahinaz M. Gadalla(Division of Cancer Epidemiology and Genetics), Pooja Khandelwal(Cincinnati Children's Hospital Medical Center), Lazaros J. Lekakis(University of Miami Hospital), Mahmoud Aljurf(King Faisal Specialist Hospital & Research Centre), Jeffery J. Auletta(Nationwide Children's Hospital), Armin Rashidi(University of Minnesota), Robert Peter Gale(Imperial College London), Stefan O. Ciurea(University of California, Irvine), Tao Wang(Medical College of Wisconsin), Miguel Ángel Díaz(Hospital Infantil Universitario Niño Jesús), Rammurti T. Kamble(Baylor College of Medicine), Jean‐Yves Cahn(Université Grenoble Alpes), Roger H. Herzig(University of Louisville), A. Samer Al‐Homsi(NYU Langone Health), Mitchell S. Cairo(New York Medical College), Joseph Pidala(Moffitt Cancer Center), Siddhartha Ganguly(University of Kansas Medical Center)
Cited by 66
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k